- Athens 2019
- Paris 2019
- ESCRS Player
- On Demand
- ESCRS iLearn
- ESCRS YO's
Session Title: Special Cases
Session Date/Time: Friday 14/02/2014 | 08:30-10:00
Paper Time: 09:10
Venue: Kosovel Hall (Level -2)
First Author: : RomeoAltafini ITALY
Co Author(s): : Sandro Soldati Pietro Viola Roberto Cian
To determine sequential intraocular pressure (IOP) changes after pars plana vitrectomy (PPV) with combined micro incision phacoemulsification (MICS) with IOL implantation and treated in the postoperative period with nepafenac therapy for a month.
Ophthalmic Unit, S.Bortolo Hospital , Vicenza, Italy
Forthy eyes of forthy patients affected by cataract and macular pucker underwent to combined PPV and MICS were reviewed for postoperative sequential IOPs and the number of IOP lowering medications used. Twenty eyes of twenty patients were treated in the postoperative period with topical fixed combination of netilmicin and dexamethasone therapy for fifteen days three times for day and then only with topical dexamethasone for fifteen days to twice a day (group A). Twenty eyes of twenty patients were treated in the postoperative period with topical no fixed combination of netilmicin and nepafenac therapy for fifteen days three times for day and then only with topical nepafenac for fifteen days to twice a day (group B). The postoperative IOP were value after 1,3,7,15 and 30 days after surgery.
The postoperative IOP change in both groups , showed a significant IOP increase from 13,8 ±2, 9 mmHg to 19,5 ±6,9 on postoperative day one (group A) and from 13,1 ±3,2 to 19 ±7,1 (group B) on postoperative day one ( p>0.01). The IOP returned to the preoperative level after seven days after surgery in both groups. IOP spikes (≥ 30 mmHg) occorred on postoperative day one in 12,2 % of patients in group A and in 11,8 % of patients in group B (p>0.01) . IOP lovering medications were prescribed for these patients, and none of the eyes shoved IOP ≥ 30 mmHg after the third postoperative days. The mean IOP changes were not significantly different between the two groups at any timepoint.
The postoperative therapy with nepafenac, a no steroid agent, not determine a significant increase in intraocular pressure in patients underwent to combined PPV and MICS with a efficacy control of postoperative inflammation and protection against inflammatory macular edema after surgery . FINANCIAL INTEREST: NONE